TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of TORRENT PHARMACEUTICALS have increased by 13.07% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 33.03 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹9,620 Cr | ₹8,508 Cr | ₹8,005 Cr | ₹7,939 Cr | ₹7,673 Cr |
| Expenses | ₹6,796 Cr | ₹6,077 Cr | ₹5,524 Cr | ₹5,769 Cr | ₹5,696 Cr |
| Operating Profit (Excl OI) | ₹2,824 Cr | ₹2,431 Cr | ₹2,480 Cr | ₹2,170 Cr | ₹1,976 Cr |
| Other Income | ₹63 Cr | ₹197 Cr | ₹57 Cr | ₹121 Cr | ₹64 Cr |
| Interest | ₹333 Cr | ₹255 Cr | ₹353 Cr | ₹451 Cr | ₹504 Cr |
| Depreciation | ₹707 Cr | ₹662 Cr | ₹658 Cr | ₹654 Cr | ₹618 Cr |
| Profit Before Tax | ₹1,847 Cr | ₹1,226 Cr | ₹1,526 Cr | ₹1,187 Cr | ₹562 Cr |
| Profit After Tax | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr |
| Consolidated Net Profit | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr | ₹436 Cr |
| Earnings Per Share (Rs) | ₹48.94 | ₹36.79 | ₹45.92 | ₹73.97 | ₹60.55 |
| PAT Margin (%) | 9.92 | 7.63 | 5.11 | 8.41 | 6.85 |
| ROE(%) | 25.38 | 20.50 | 13.18 | 23.49 | 21.47 |
| ROCE(%) | 24.28 | 20.32 | 14.35 | 17.62 | 15.28 |
| Total Debt/Equity(x) | 0.57 | 0.85 | 0.68 | 0.83 | 1.21 |
Key Financials |
||
| Market Cap | : | ₹ 114,040.8 Cr |
| Revenue (TTM) | : | ₹ 10,996.0 Cr |
| Net Profit(TTM) | : | ₹ 1,735.0 Cr |
| EPS (TTM) | : | ₹ 51.3 |
| P/E (TTM) | : | 65.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TORRENT PHARMACEUTICALS | -0.6% | -1% | 80.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.8% | 5.7% | 69.5% |
| CIPLA | 2.1% | 0.2% | 42.9% |
| DR REDDYS LABORATORIES | -0.1% | -1.8% | 24.4% |
| ZYDUS LIFESCIENCES | 0.1% | -4% | 79.3% |
| DIVIS LABORATORIES | 0.9% | 7.2% | 48% |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 13.07 % |
| 5 Yr CAGR | 5.82 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹9,620 Cr | 13.07 | |
| Mar2023 | ₹8,508 Cr | 6.29 | |
| Mar2022 | ₹8,005 Cr | 0.82 | |
| Mar2021 | ₹7,939 Cr | 3.47 | |
| Mar2020 | ₹7,673 Cr | - | |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 16.15 % |
| 5 Yr CAGR | 9.33 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,824 Cr | 16.15 | |
| Mar2023 | ₹2,431 Cr | -1.97 | |
| Mar2022 | ₹2,480 Cr | 14.27 | |
| Mar2021 | ₹2,170 Cr | 9.81 | |
| Mar2020 | ₹1,976 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 2.69 % |
| 5 Yr CAGR | 3.32 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 29.35% | 2.69 | |
| Mar2023 | 28.58% | -7.75 | |
| Mar2022 | 30.98% | 13.31 | |
| Mar2021 | 27.34% | 6.13 | |
| Mar2020 | 25.76% | - | |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 60.22 % |
| 5 Yr CAGR | 29.98 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,245 Cr | 60.22 | |
| Mar2023 | ₹777 Cr | -37.92 | |
| Mar2022 | ₹1,252 Cr | 22.17 | |
| Mar2021 | ₹1,025 Cr | 134.88 | |
| Mar2020 | ₹436 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 30.01 % |
| 5 Yr CAGR | 9.70 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 9.92 % | 30.01 | |
| Mar2023 | 7.63 % | 49.32 | |
| Mar2022 | 5.11 % | -39.24 | |
| Mar2021 | 8.41 % | 22.77 | |
| Mar2020 | 6.85 % | - | |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 33.03 % |
| 5 Yr CAGR | -5.18 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹49 | 33.03 | |
| Mar2023 | ₹37 | -19.88 | |
| Mar2022 | ₹46 | -37.92 | |
| Mar2021 | ₹74 | 22.16 | |
| Mar2020 | ₹61 | - | |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 19.49 % |
| 5 Yr CAGR | 12.27 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 24.28% | 19.49 | |
| Mar2023 | 20.32% | 41.60 | |
| Mar2022 | 14.35% | -18.56 | |
| Mar2021 | 17.62% | 15.31 | |
| Mar2020 | 15.28% | - | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹3,370.0 |
| Current MarketCap | : | ₹ 114,040.8 Cr |
| Updated EOD on | : | Oct 01,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | -0.6% |
-1% |
80.6% |
| SENSEX | -0.8% |
2.3% |
27.8% |
TORRENT PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE QUALITY | 0.7% | 0.5% | 55% |
| S&P BSE HEALTHCARE | 0.1% | 2.5% | 59.4% |
| S&P BSE MIDSMALLCAP | -0.2% | 1.8% | 54.4% |
| S&P BSE MID CAP | -0.3% | 0.9% | 54.3% |
| S&P BSE ALLCAP | -0.4% | 2.1% | 40.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY ALPHA QTY LOW-VOLAT.30 | 0.6% | 3% | 58.1% |
| NIFTY PHARMA | -0.3% | 0.8% | 52.9% |
| NIFTY HEALTHCARE | -0.4% | 1.5% | 52.7% |
| NIFTY 100 ALPHA 30 | -0.9% | -0.8% | 70.4% |
| NIFTY NEXT 50 | -1.4% | 0.2% | 66.8% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 13.07% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 33.03 % YoY .
Check out Intrinsic Value of Peers of TORRENT PHARMACEUTICALS
Compare Stock Analytics of Peers of TORRENT PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
